Tools   Select Another Resource Report Type

http://www.mc.pref.osaka.jp/omc2/eng/index.html

Center for cancer and cardiovascular diseases with a focus on advanced cancer therapy in the Kansai area. It consists of the Hospital, the Research Institute, and the Department of Cancer Control and Statistics. The Research Institute is responsible for acquiring and applying knowledge of the molecular and genetic aspects of human cancer. The mission of the Research Institute is to perform basic and applied cancer research through collaboration with the Hospital and the Department of Cancer Control and Statistics. The large tumor tissue collection is the major focus of their research efforts. The Research Institute includes seven official departments: Biology, Biochemistry, Pathology, Molecular Medicine & Pathophysiology, Molecular Biology, Molecular Genetics, and Immunology. In addition, a group conducted by the Director (Director''s Unit) and Laboratory of Genome Informatics. The research objectives are as follows. # Clinical research. ## Prognosis predictor of gliomas based on gene expression profiling ## Targeted oncolytic virus # Technical developments for cancer research ## A new method for storing cancer cells taken from human tumor tissues (cancer tissue-originated spheroid) ## Bioinformatics for personalized genomics # Basic research ## Mechanism of metastasis ## Low oxygen environment and cancer ## Structure analysis of oligosaccharide on human cancer cells ## Proof-of-principle study of artificial adjuvants

Proper citation: Osaka Medical Center for Cancer and Cardiovascular Diseases; Osaka; Japan (RRID:SCR_011477) Copy   

•   Source: SciCrunch Registry

http://bioinfo-out.curie.fr/projects/snp_gap/

Software for automatic detection of absolute segmental copy numbers and genotype status in complex cancer genome profiles measured by single-nucleotide polymorphism (SNP) arrays. The method is based on pattern recognition of segmented and smoothed copy number and allelic imbalance profiles. The method performs well even for poor-quality data, low tumor content, and highly rearranged tumor genomes.

Proper citation: Genome Alteration Print (RRID:SCR_012016) Copy   

•   Source: SciCrunch Registry

http://www.dkfz.de/index.html

Biomedical research institute in Germany that investigates the mechanisms of cancer and works to identify cancer risk factors. They provide the foundations for developing novel approaches in the prevention, diagnosis, and treatment of cancer and are a member of the Helmholtz Association of National Research Centers. Professor Harald zur Hausen was awarded the Nobel Prize for Medicine for his outstanding scientific contribution to the study of human papillomaviruses (HPV). In addition, the staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The Center is funded by the German Federal Ministry of Education and Research (90%) and the State of Baden-Württemberg (10%).

Proper citation: German Cancer Research Center (RRID:SCR_012942) Copy   

•   Source: SciCrunch Registry

http://www.ucl.ac.uk/biobank/

Two University College London (UCL) biobanks, one based at the Royal Free Hospital (RFH) Campus and the other based at Bloomsbury supporting Pathology and the Cancer Institute, will act as physical repositories for collections of biological samples and data from patients consented at UCLH, Partners Hospitals and external sources. This will incorporate collections of existing stored samples and new collections. UCL-RFH BioBank, the physical repository at the Royal Free, presents a unique opportunity to advance medical research through making access to research tissue easier, faster and much more efficient. The BioBank is both a physical repository, with capacity for up to 1 million cryogenically stored samples and a virtual repository for all tissue, cell, plasma, serum, DNA and RNA samples stored throughout UCLP. In particular, samples considered "relevant material", such as tissues and cells, that are licensed by the Human Tissue Authority, can be stored long term. Existing holdings of tissues and cells where appropriate can be transferred to the Physical BioBank at the Royal Free. UCL - Royal Free BioBank provides a flexible approach to banking, allowing the Depositor to pick and choose services that are tailored to fit their requirements. Collaborations arising from publicizing of the existence of the holdings are entirely at the discretion of the depositor, as the facility ensures that access to the deposits remains at the decision of the Depositor/User. UCL Biobank for studying Health and Disease (based at Pathology-Rockefeller building and the UCL-Cancer Institute will support projects principally involved in the study of human disease. The aim is to support primarily, research in the Pathology Department, UCLH and the UCL-Cancer Institute but it will also support other UCLH partners. The biobank will store normal and pathological specimens, surplus to diagnostic requirements, from relevant tissues and bodily fluids. Stored tissues will include; snap-frozen or cryopreserved tissue, formalin-fixed tissue, paraffin-embedded tissues, and slides prepared for histological examination. Tissues will include resection specimens obtained surgically or by needle core biopsy. Bodily fluids will include; whole blood, serum, plasma, urine, cerebrospinal fluid, milk, saliva and buccal smears and cytological specimens such as sputum and cervical smears. Fine needle aspirates obtained from tissues and bodily cavities (e.g. pleura and peritoneum) will also be collected. Where appropriate the biobank will also store separated cells, protein, DNA and RNA isolated from collected tissues and bodily fluids described above. Some of the tissue and aspirated samples will be stored in the diagnostic archive.

Proper citation: UCL Biobank (RRID:SCR_000517) Copy   

•   Source: SciCrunch Registry

http://cancergenome.nih.gov/

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

Proper citation: The Cancer Genome Atlas (RRID:SCR_003193) Copy   

•   Source: SciCrunch Registry

http://www.bcgsc.ca/project/pleiades-promoter-project

Project to generate human DNA promoters of less than 4 kb (MiniPromoters) to drive gene expression in defined brain regions of therapeutic interest for diseases such as Alzheimer, Parkinson, Huntington, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinocerebellar Ataxia, Depression, Autism, and Cancer. Project develops and shares tools like human MiniPromoters that drive region- and cell-specific gene expression in the mouse brain, expression constructs, mouse embryonic stem cell lines, and knock-in mice all of which carry brain-specific MiniPromoters. Project is daughter of Genome Canada Project, Atlas of Gene Expression in Mouse Development, within which mouse brain gene expression data have already been gathered. Project team has collaborated with International BioPharma Solutions Ltd., management and communications consulting company specializing in product development and commercialization advice. Project will explore challenging interface between science and journalism with focus on genomics and gene therapy.

Proper citation: Pleiades Promoter Project: Genomic Resources Advancing Therapies for Brain Disorders (RRID:SCR_003282) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/research/ki-biobank

KI Biobank is an accredited core facility offering sample collection services. KI Biobank is located at the Department of Medical Epidemiology and Biostatistics. KI Biobank offer infrastructure for pre analytical sample handling and provide researchers guidance on how samples should be taken and labeled. The processes comprise registration, handling, storage and distribution of samples. KI Biobank also offers DNA-extraction from blood and saliva. In order to insure complete traceability on samples and belonging information all processes are controlled by a Laboratory Information Management System (LIMS). For every new study a contract is established describing the study and the disposition rights. We also help in writing Biobank agreements including multicenteravtal and Material Transfer Agreement. KI Biobank is, according to the Biobank law, responsible for all sample collections handled within the core facility and those that are stored on the departments on KI campus. Clinical sample collections are handled by the Biobank units at the respective hospitals within the Stockholm County Council. Besides the samples that are stored centrally at KI Biobank, KI Biobank is also the administrative biobank for research sample collections at Karolinska Institutet that are stored and administrated at the departments. All research sample collections must be reported to KI Biobank. The following types of sample collections are registered in the biobank; sample collections taken within the regular health care that has been transferred to Karolinska Institutet with an agreement of transfer, samples taken from healthy individuals or other persons out of the regular health care and samples that have been taken abroad.

Proper citation: Karolisnka Biobank (RRID:SCR_004355) Copy   

•   Source: SciCrunch Registry

http://www.rbcsyd.se/

To meet the law requirements and regulations of the National Board of the Southern Health Care Region, Region Skane and Lund University agreed to establish a common biobanking center for Southern healthcare region. Regional biobanksrcentrum will develop and maintain systems for quality assurance and integrity protected using biobanks. The Regional Biobank center is responsible for matters relating to the collection, storage and use of samples stored in biobanks in the Southern healthcare region. Regional Biobank center operations consist of: * to promote the use of biobank material is in accordance with legal requirements biobank * to promote integrity protected and safe storage of repository material * to provide information about the biobank law and biobank materials used for individual sample donors, health professionals, researchers and the public * to handle requests for modified consent and desire to destroy or de test * maintaining a current and privacy protected records of repository material in the region * work to the individual''s integrity will be strengthened in relation to research on biobank material. Tissue samples available to other parties, by surrendering, or by sending tissue samples for analysis, requiring the return or destruction, after completion of the analysis. Regional Biobank Centre (RBC) for the southern healthcare region was established in 2004 and was until 2010 in the Oncology Centre. As of January 1, 2011 it is under the management of RBC Labmedicin Skane.

Proper citation: Swedish Regional Biobank (RRID:SCR_004503) Copy   

•   Source: SciCrunch Registry

http://www.kreftregisteret.no/en/Research/Janus-Serum-Bank/

The Janus Serum Bank has blood samles from 317 000 Norwegians. The biobank is reserved for cancer research, and is internationally unique regarding size and number of cancer cases. The Janus Serum Bank is a population based biobank reserved for cancer research. The specimens are collected during the period from 1972-2004 and are stored at 25 degrees Celsius. The samples originate from 317 000 persons in Norway who have participated in health studies and also from blood donors in and around Oslo. Today, samples are only collected from earlier donors in the Janus Serum Bank who have developed cancer. The Bank is internationally unique regarding size and number of cancer cases. Annual linkage to the Cancer Registry shows that 52 500 donors are diagnosed with cancer as of December 31, 2009. The main goals of the biobank are to make the material available to cancer researchers over the whole world and deliver quality assured samples and data. The Janus Serum Bank is registered in the Biobank Register (Notification number 737)

Proper citation: Janus Serum Bank (RRID:SCR_005885) Copy   

•   Source: SciCrunch Registry

http://www.cancerbiobank.org/

CCPRB (Cancer Control using Population-based Registries and Biobanks) is a Network of Excellence project within the sixth framework programme of the European Union. It is aiming at improved control of cancer by facilitating research linking biobanks and cancer registries. The project involves a systematic quality assurance and continuous development of standards and norms for human sample biobanks in Europe, as well as development of improved integrity-protection standards in the handling of sensitive information in connection with biobank-based research. The samples in the biobanks will be used in large-scale cancer research searching for genetic and infectious causes to cancer, in particular in the areas of breast and colorectal cancer and childhood leukemia. Project objectives: * Provide the study base for uniquely large population-based prospective studies on cancer * Define and implement a generally applicable European Quality Standard for Biobanking that will include improved data and specimen standardization, acquisition and analysis, reliable and standardized statistical analysis as well as improved management and co-ordination of European biobanks. * Define and promote the implementation of integrity-proof methods for biobank-based research involving well defined and secure third party code-keeping systems. * Enable large-scale, population-based research on: ** evaluation of cancer treatment and role of molecular markers in treatment selection ** use over-generation registry linkages applied to large biobank cohorts to identify and evaluate genetic predisposition associated with increased cancer risk as well as interactions with common environmental exposures. ** use over-generation registry linkages applied to large biobank cohorts to explore and evaluate intrauterine exposures associated with increased cancer risk ** exploit the power of large population cohorts for design of optimal strategies for cancer prevention and its evaluation. * Establish a Europe-wide network for spreading the awareness of i) the data, samples and knowledge generated European biobank-based research ii) possibilities for future biobank-based research and iii) the best practice quality standards for biobank-based research.

Proper citation: Cancer Control using Population-based Registries and Biobanks (RRID:SCR_004902) Copy   

•   Source: SciCrunch Registry

http://www.dna-network.ac.uk/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 6, 2011. A project to collect, store and study DNA samples from tens of thousands of healthy volunteers and patients with diseases of major public importance. It aims to identify genes that are risk factors for the conditions. The network consists of 13 collections led by different clinicians throughout the UK. At its heart is an archive infrastructure which manages the DNA and the information associated with it. The European Collection of Cell Cultures in Porton Down handles the blood, peripheral blood lymphocytes and EBV-transformed cell lines, while the Centre for Integrated Genomic Medical Research at Manchester University manages the DNA. These banked samples are available to UK and international researchers, who can examine data and set up collaborative work by registering at the DNA Network's website. The conditions for which samples are currently collected and stored are: Acute leukemia, Asthma and eczema, Late onset Alzheimer's disease, Breast cancer, Colorectal cancer, Coronary artery disease, Glomerulonephritis, Hypertension, Age-related macular degeneration, Multiple sclerosis, Parkinson's disease, Type 2 diabetes, Unipolar depression.

Proper citation: UK DNA Banking Network (RRID:SCR_010619) Copy   

•   Source: SciCrunch Registry

http://www.istge.it/crb/english.htm

The Centro di Risorse Biologiche (CRB-IST), institutional facility of IST, has been recently established by the General Director (Deliberation number 624 July 11, 2008). It aims at co-ordinating already existing biobanking activities, and participating in the European Infrastructure of Biobanks and Biomolecular Resources (BBMRI), in preparation in the frame of the 7th FP of the European Community. Aims: * to facilitate high quality translational research dependent on biological material and data * to address ethical issues on biobanking * to promote the project at the population level * to co-ordinate the IST biobanks and cell banks * to harmonize technical and management SOPs, according to international best practices * to help reduce costs for collection and storage of biological material * to favor institutional recognition at a regional, national and international level - to sustain the role of the Institute in the European infrastructure.

Proper citation: Biological Resource Centre - National Institute for Cancer Research (RRID:SCR_010548) Copy   

•   Source: SciCrunch Registry

https://seer.cancer.gov/statfacts/

Collection of statistical summaries for number of common cancer types. They were developed to provide quick overview of frequently requested cancer statistics. Available statistics may include incidence, mortality, survival, stage, prevalence, and lifetime risk. Links to additional resources from NCI including risk factors, treatment, and clinical trials are also provided. The statistics will be updated annually to coincide with the SEER data release.

Proper citation: National Cancer Institute Cancer Statistics Cancer Stat Facts (RRID:SCR_024437) Copy   

•   Source: SciCrunch Registry

http://bmsr.usc.edu/

Biomedical technology resource center dedicated to the advancement of the state-of-the-art in biomedical modeling and simulation through Core and Collaborative Research projects, as well as the dissemination of this knowledge and related software through Service, Training and Dissemination activities aimed at the biomedical community at large. The BMSR includes four core research projects: * Pharmacokinetic/Pharmacodynamic Systems Analysis * Nonlinear Modeling of Complex Biomedical Systems * Modeling of Autonomic, Metabolic and Vascular Control Interactions * Nonlinear Modeling of the Hippocampus Fifteen Collaborative Research Projects serve as challenging test grounds for the Resource's methodologies and expertise.

Proper citation: Biomedical Simulations Resource (RRID:SCR_001952) Copy   

•   Source: SciCrunch Registry

http://www.hms.harvard.edu/NEPRC/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 12,2023. A U.S. Regional Primate Research Center that focuses on AIDS, cancer, neuropsychiatric disorders, drug addiction, and neurodegenerative disease. The Division of Primate Resources provides researchers with the services and facilities to support biomedical research. It offers a broad spectrum of services ranging from analysis of tissue specimens to partnership investigations with leading biomedical research institutions. Outside investigators have access to tissue specimens, organs, blood, skeletal structures, and viral specimens. Services include veterinary services, animals and animal care, surgical and radiographic services, timed mating, biocontainment, pathology services, and professional and technical expertise. Additional diagnostic and research services at NEPRC include testing for antiviral antibodies, DNA cloning, and DNA sequencing. The colony of nine species includes rhesus macaques and other Old World monkeys and New World species including the common marmoset and squirrel monkey. Other species can be obtained. Animals with exceptional characteristics (specific-pathogen-free, timed pregnancy, surgically altered, etc.) can be made available if needed. Scientists wishing to conduct research at the center must have projects reviewed and approved by the center animal allocation committee.

Proper citation: New England National Primate Research Center (RRID:SCR_002887) Copy   

•   Source: SciCrunch Registry

http://www.lyonbiopole.com/index-en.html

A worldwide competitiveness cluster centered on pharmaceutical activities including the fight against human and animal infectious diseases and cancers. Designed as a tool interface and public / private approximation, the division has implemented measures to encourage collaborative R & D, help in setting up projects and find funding, increase strategic and financial partnerships for economic development and international companies, provide access to reception areas, technological shared platforms such as the Infectious Diseases Center Lyonbiop��le. It aims to strengthen the competitiveness of the sector health and the attractiveness of the Rh��ne-Alpes area, mainly on the Lyon-Grenoble axis. (adapted from the translated Wikipedia)

Proper citation: Lyonbiopole (RRID:SCR_003733) Copy   

•   Source: SciCrunch Registry

http://www.thesgc.org/

Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery.Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets.

Proper citation: Structural Genomics Consortium (RRID:SCR_003890) Copy   

•   Source: SciCrunch Registry

http://www.eortc.org/clinical-trials

A database that contains information about EORTC (European Organisation for Research and Treatment of Cancer) clinical trials but also clinical trials from other organizations, in which EORTC has been/is participating. The protocol database may be browsed by EORTC Research Group, tumor site, treatment, or drug.

Proper citation: EORTC Clinical Trials (RRID:SCR_004011) Copy   

•   Source: SciCrunch Registry

http://norccentral.org

Portal to research centers and core facilities specifically support obesity research and better understand the relationship between health and nutrition.

Proper citation: Nutrition and Obesity Research Centers (RRID:SCR_004131) Copy   

•   Source: SciCrunch Registry

http://www.dukecancerinstitute.org/

One of 40 centers in the country designated by the National Cancer Institute (NCI) as a comprehensive cancer center, it combines cutting-edge research with compassionate care. Its vision is to accelerate research advances related to cancer and improve Duke''s ability to translate these discoveries into the most advanced cancer care to patients by uniting hundreds of cancer physicians, researchers, educators, and staff across the medical center, medical school, and health system under a shared administrative structure.

Proper citation: Duke Cancer Institute (RRID:SCR_004338) Copy   

•   Source: SciCrunch Registry